A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop bispecific antibody-based T-cell engager (TCE) therapies for autoimmune diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,